{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:09:47Z","timestamp":1791828587925,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40744-024-00671-4","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T12:02:06Z","timestamp":1714392126000},"page":"737-753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-1131","authenticated-orcid":false,"given":"Gerd R.","family":"Burmester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Stigler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rubbert-Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valderilio F.","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Coombs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Lagunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Lippe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne S.","family":"Gensler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"671_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.berh.2012.01.002","volume":"26","author":"M Ehrenfeld","year":"2012","unstructured":"Ehrenfeld M. Spondyloarthropathies. Best Pract Res Clin Rheumatol. 2012;26:135\u201345.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"671_CR2","doi-asserted-by":"publisher","first-page":"896","DOI":"10.7326\/0003-4819-136-12-200206180-00011","volume":"136","author":"MA Khan","year":"2002","unstructured":"Khan MA. Update on spondyloarthropathies. Ann Intern Med. 2002;136:896\u2013907.","journal-title":"Ann Intern Med"},{"key":"671_CR3","doi-asserted-by":"publisher","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","volume":"58","author":"GE Fragoulis","year":"2019","unstructured":"Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford). 2019;58:i43\u201354.","journal-title":"Rheumatology (Oxford)"},{"key":"671_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Luo Y, O\u2019Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18:133\u201345.","journal-title":"Nat Rev Rheumatol"},{"key":"671_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","volume":"18","author":"MA Adas","year":"2022","unstructured":"Adas MA, Alveyn E, Cook E, Dey M, Galloway JB, Bechman K. The infection risks of JAK inhibition. Expert Rev Clin Immunol. 2022;18:253\u201361.","journal-title":"Expert Rev Clin Immunol"},{"key":"671_CR6","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326.","journal-title":"N Engl J Med"},{"key":"671_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, Landewe RBM, Van den Bosch FE, Boteva B, Bremander A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82:19\u201334.","journal-title":"Ann Rheum Dis"},{"key":"671_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002236","volume":"8","author":"TW Kragstrup","year":"2022","unstructured":"Kragstrup TW, Glintborg B, Svensson AL, McMaster C, Robinson PC, Deleuran B, Liew DF. Waiting for JAK inhibitor safety data. RMD Open. 2022;8: e002236.","journal-title":"RMD Open"},{"key":"671_CR9","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","volume":"80","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Lertratanakul A, Anderson JK, Papp K, Van den Bosch F, Tsuji S, Dokoupilova E, Keiserman M, Wang X, Zhong S, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2021;80:312\u201320.","journal-title":"Ann Rheum Dis"},{"key":"671_CR10","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","volume":"384","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Anderson JK, Magrey M, Merola JF, Liu Y, Kishimoto M, Jeka S, Pacheco-Tena C, Wang X, Chen L, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021;384:1227\u201339.","journal-title":"N Engl J Med"},{"key":"671_CR11","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Everding A, Sui Y, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet. 2019;394:2108\u201317.","journal-title":"Lancet"},{"key":"671_CR12","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/ard-2022-222608","volume":"81","author":"D van der Heijde","year":"2022","unstructured":"van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman RD, Kameda H, Zeng X, Sui Y, Bu X, Pangan AL, et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis. 2022;81:1515\u201323.","journal-title":"Ann Rheum Dis"},{"key":"671_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","volume":"400","author":"A Deodhar","year":"2022","unstructured":"Deodhar A, Van den Bosch F, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH, Kishimoto M, Blanco R, Duan Y, Li Y, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400:369\u201379.","journal-title":"Lancet"},{"key":"671_CR14","unstructured":"US Food and Drug Administration. Highlights of prescribing information [upadacitinib]. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/211675s012lbl.pdf. Accessed 22 April 2024."},{"key":"671_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735","volume":"9","author":"GR Burmester","year":"2023","unstructured":"Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, et al. Safety profile of upadacitinib over 15000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9: e002735.","journal-title":"RMD Open"},{"issue":"3","key":"671_CR16","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","volume":"80","author":"SB Cohen","year":"2020","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL, Zerbini CAF, Tanaka Y, Bessette L, Zhang Y, Khan N, Hendrickson B, Enejosa JV, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2020;80(3):304\u201311.","journal-title":"Ann Rheum Dis"},{"key":"671_CR17","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","volume":"80","author":"V Navarro-Compan","year":"2021","unstructured":"Navarro-Compan V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis. 2021;80:1511\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"671_CR18","doi-asserted-by":"publisher","first-page":"i77","DOI":"10.1136\/ard.2010.140582","volume":"70","author":"PJ Mease","year":"2011","unstructured":"Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis. 2011;70(Suppl 1):i77\u201384.","journal-title":"Ann Rheum Dis"},{"key":"671_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","volume":"77","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Schols M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewe R, Mease P, Sieper J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77:3\u201317.","journal-title":"Ann Rheum Dis"},{"key":"671_CR20","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/acr.24025","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, et al. 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71:1285\u201399.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"671_CR21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/nrrheum.2017.51","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13:320.","journal-title":"Nat Rev Rheumatol"},{"key":"671_CR22","doi-asserted-by":"publisher","first-page":"162","DOI":"10.55563\/clinexprheumatol\/cpu6r9","volume":"40","author":"KL Winthrop","year":"2022","unstructured":"Winthrop KL, Tanaka Y, Lee EB, Wollenhaupt J, Al Enizi A, Azevedo VF, Curtis JR. Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review. Clin Exp Rheumatol. 2022;40:162\u201372.","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"671_CR23","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s11926-023-01111-y","volume":"25","author":"R Venkat","year":"2023","unstructured":"Venkat R, Wallace ZS, Sparks JA. Considerations for pharmacologic management of rheumatoid arthritis in the COVID-19 era: a narrative review. Curr Rheumatol Rep. 2023;25(11):236\u201345.","journal-title":"Curr Rheumatol Rep."},{"key":"671_CR24","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3899\/jrheum.210888","volume":"49","author":"JR Curtis","year":"2022","unstructured":"Curtis JR, Zhou X, Rubin DT, Reinisch W, Yazdany J, Robinson PC, Chen Y, Benda B, Madsen A, Geier J. Characteristics, comorbidities, and outcomes of SARS-CoV-2 infection in patients with autoimmune conditions treated with systemic therapies: a population-based study. J Rheumatol. 2022;49:320\u20139.","journal-title":"J Rheumatol"},{"key":"671_CR25","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1186\/s12889-022-14567-x","volume":"22","author":"M Sobczak","year":"2022","unstructured":"Sobczak M, Pawliczak R. COVID-19 mortality rate determinants in selected Eastern European countries. BMC Public Health. 2022;22:2088.","journal-title":"BMC Public Health"},{"key":"671_CR26","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1007\/s12325-023-02533-x","volume":"40","author":"Y Ye","year":"2023","unstructured":"Ye Y, Yue X, Krueger WS, Wegrzyn LR, Maniccia AW, Winthrop KL, Kim SC. Factors associated with severe COVID-19 among patients with rheumatoid arthritis: a large, nationwide electronic health record cohort study in the United States. Adv Ther. 2023;40:3723\u201338.","journal-title":"Adv Ther"},{"key":"671_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002871","volume":"9","author":"AP Tran","year":"2023","unstructured":"Tran AP, Tassone DF, Ding NS, Nossent J. Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2). RMD Open. 2023;9: e002871.","journal-title":"RMD Open"},{"key":"671_CR28","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1186\/s12935-021-02325-9","volume":"21","author":"R Liu","year":"2021","unstructured":"Liu R, Wan Q, Zhao R, Xiao H, Cen Y, Xu X. Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis. Cancer Cell Int. 2021;21:614.","journal-title":"Cancer Cell Int"},{"key":"671_CR29","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.therap.2022.04.005","volume":"77","author":"C Jalles","year":"2022","unstructured":"Jalles C, Lepelley M, Mouret S, Charles J, Leccia MT, Trabelsi S. Skin cancers under Janus kinase inhibitors: a World Health Organization drug safety database analysis. Therapie. 2022;77:649\u201356.","journal-title":"Therapie"},{"key":"671_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003392","volume":"9","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman C, Choy E, McInnes IB, Mysler E, Nash P, Yamaoka K, Lippe R, Khan N, Shmagel AK, Palac H, et al. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 2023;9: e003392.","journal-title":"RMD Open"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00671-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-024-00671-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00671-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T15:32:20Z","timestamp":1716391940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-024-00671-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["671"],"URL":"https:\/\/doi.org\/10.1007\/s40744-024-00671-4","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"assertion":[{"value":"15 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Derek Coombs and Ivan Lagunes were involved in the acquisition of data. Gerd R. Burmester, Jayne Stigler, Andrea Rubbert-Roth, Yoshiya Tanaka, Valderilio F. Azevedo, Derek Coombs, Ivan Lagunes, Ralph Lippe, Peter Wung, and Lianne S. Gensler were involved in the analysis and interpretation of the data, drafting the article, and revising it for critically important intellectual content, and approving the final version of manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"AbbVie Inc. (North Chicago, IL, USA) funded these trials (NCT03104400, NCT03104374, NCT03178487, NCT04169373) and participated in the trial design, research, analysis, data collection, interpretation of data, and the review and approval of the publication. AbbVie Inc. (North Chicago, IL, USA) funded the journal\u2019s Rapid Service Fee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (eg, protocols, clinical study reports, or\u00a0analysis plans), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.\u00a0These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent, scientific research, and will be provided following review and approval of a research proposal, Statistical Analysis Plan (SAP), and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time after approval in the US and Europe and after acceptance of this manuscript for publication.\u00a0The data will be accessible for 12\u00a0months, with possible extensions considered. For more information on the process or to submit a request, visit the following link:  then select \u201cHome\u201d.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"These trials were conducted according to the International Conference on Harmonization guidelines, the Declaration of Helsinki principles, and applicable local country regulations. All study-related documents were approved by independent ethics committees and institutional review boards at each site. All patients provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Gerd R. Burmester has received honoraria for consulting and lecture from AbbVie, Janssen, Novartis, and Pfizer. Andrea Rubbert-Roth has received honoraria for lectures and consulting fees from AbbVie, Amgen, BMS, Chugai, Eli Lilly, Gilead, Janssen, Novartis, Roche, and Sanofi. Yoshiya Tanaka has received speaker fees and\/or honoraria from Eli Lilly, AstraZeneca, Abbvie, Asahi Kasei, Gilead, Chugai, Boehringer-Ingelheim, GlaxoSmithKline, Eisai, Taisho, BMS, Pfizer\u00a0and, Taiho; received research grants from Asahi Kasei, Mitsubishi-Tanabe, Eisai, Chugai, and Taisho. Yoshiya Tanaka\u00a0is also\u00a0an Editorial Board member\u00a0of <i>Rheumatology and Therapy<\/i>, however\u00a0was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Valderilio F. Azevedo has received funding for clinical trials, research grants, and\/or honoraria for lectures and advice from AbbVie, Amgen, Bristol-Myers Squibb, Celltrion, Eli Lilly, Fresenius Kabi, GSK, Janssen, Novartis, Organon, Pfizer, and UCB. Jayne Stigler, Derek Coombs, Ivan Lagunes, Ralph Lippe, and Peter Wung are employees of AbbVie Inc. and may hold stock or options. Lianne S. Gensler has received grants from Novartis and UCB Pharma paid to her institution and consulting fees from AbbVie, Fresenius Kabi, Gilead, Janssen, Eli Lilly, MoonLake, Novartis, Pfizer, and UCB Pharma.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}